

# The Pharma Legal Handbook

---

# Spain

Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical  
Trial Requirements · Marketing, Manufacturing, Packaging and Labeling  
Advertising · Traditional Medicines and OTC Products · Product Liability  
· Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs,  
Medicinal Cannabis and Opioid Drugs

# Spain

**The Pharma Legal Handbook answers essential questions about this environment for pharmaceuticals in Spain. It is a must have for any company operating in the country or looking to enter the market.**

**Prepared in association with Faus & Moliner Abogados, a leading Spanish law firm, it should answer any questions linked to Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks and Patents.**

PharmaBoardroom is not responsible for any mistakes contained within this publication. For specific advice on any legal issue, please contact a qualified professional.

Copyright: All rights reserved. No part of this publication may be reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

**\* THIS REPORT WAS ORIGINALLY PUBLISHED IN JULY 2019 AND THE INFORMATION CONTAINED WITHIN IS SUBJECT TO CHANGE.**

## Faus & Moliner Abogados

Faus & Moliner Abogados is a modern boutique law firm, specialised in dealing with legal matters typical of the pharmaceutical industry and other companies which operate in the “life sciences” sector. Faus & Moliner, which was founded in 1997, focuses on pharmaceutical law, commercial contracts, corporate transactions, corporate governance, compliance, competition law, public procurement, product liability, advertising, litigation and arbitration. The firm advises pharma and healthcare clients, acts on behalf of large companies and smaller biotech start-ups, and is frequently called upon to advise public authorities on matters such as draft legislation.

The Firm decided to pursue this specialisation route because its founding partners were convinced that they would be able to create more value for clients if they not only offered solid legal skills, both theoretical and practical, but also a deep knowledge of the social and economic environment of the sector in which their clients operate.

The Firm combines legal skills and specialization with a practical and business-oriented manner of practicing law. This allows Faus & Moliner Abogados to offer innovative solutions and at the same time to provide adequate responses to the cases which are entrusted to us. Nowadays, the Firm is formed by ten lawyers all of them specialized in the “life sciences” sector. Since its foundation in 1997, Faus & Moliner has been the market leader in the area of pharmaceutical law in Spain as recognized in several international publications.

# THE AUTHORS

---



**EDUARD  
RODELLAR**

---

Eduard Rodellar, a partner, is a member of Faus & Moliner since 1998. He has wide experience in providing legal assistance on a great variety of matters typical of the pharmaceutical industry and other companies operating in the life sciences sector, especially in the areas of mercantile and procedural law. He is specialized in clinical trials and data privacy. Mr. Rodellar has a Law Degree from the University Pompeu Fabra, a Master's degree in Legal Practice from the Barcelona Bar Association and a Master's degree in Business, Tax and Legal Advice from ESADE.

Languages: Spanish, Catalan, English and French



**VERÓNICA  
CARÍAS**

---

Verónica Carías, a senior associate, is specialized in pharmaceutical law and international commercial contracts. She has experience in providing legal advice on contractual matters to companies of the pharmaceutical sector, having skills for both drafting and negotiating agreements on behalf of clients. Ms. Carías has a Law Degree and a Full time Master of Laws (LL.M.) on Corporate Law and Business Administration, "Instituto de Empresa", IE Law School, Madrid.

Languages: Spanish and English.



**LLUIS  
ALCOVER**

---

Lluís Alcover, a senior associate, is specialized in investment operations, restructuring and due diligence processes, as well as in the drafting and negotiation of all types of commercial contracts. He regularly advises national and international clients in the areas of the activities described. Mr. Alcover has a Law Degree from the University Pompeu Fabra, an Economics Degree from the University Pompeu Fabra, a Master's degree in Business, Tax and Legal Advice from ESADE, and a Management Development Plan (PDD), at ESADE.

Languages: Spanish, Catalan and English.



**LAURA  
MARQUÈS**

---

Laura Marquès, an associate, is specialized in competition law. Ms. Marquès has a Law Degree from ESADE, a Double Master in Legal Practice and International Law from ESADE and Università Commerciale Luigi Bocconi in Milan, and a LL.M. in competition law from King's College London.

Languages: Spanish, Catalan, English and Italian.



**JUAN  
MARTÍNEZ**

---

Juan Martínez, a junior associate, is specialized in pharmaceutical law, particularly in product liability and procedural matters. Mr. Martínez has Law Degree from the University of Granada, and a Master of Legal Practice with a specialization in International Business Law at the Garrigues Studies Center.

Languages: Spanish and English.



## Faus & Moliner Abogados

*Leading law firm  
in life sciences in Spain*

Rambla Catalunya 135  
08008 Barcelona

+34 93 292 21 00  
[bcn@faus-moliner.com](mailto:bcn@faus-moliner.com)

[www.faus-moliner.com](http://www.faus-moliner.com)

# CONTENTS

---

---

<b>01</b>	<b>REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW</b>	Page 6
-----------	--	--------

---

<b>02</b>	<b>PRECLINICAL AND CLINICAL TRIAL REQUIREMENTS</b>	Page 13
-----------	--	---------

---

<b>03</b>	<b>MARKETING, MANUFACTURING, PACKAGING AND LABELING ADVERTISING</b>	Page 17
-----------	---	---------

---

<b>04</b>	<b>TRADITIONAL MEDICINES AND OVER-THE-COUNTER PRODUCTS</b>	Page 28
-----------	--	---------

---

<b>05</b>	<b>PRODUCT LIABILITY</b>	Page 34
-----------	--------------------------	---------

---

<b>06</b>	<b>PATENTS AND TRADEMARKS</b>	Page 38
-----------	-------------------------------	---------

---

<b>07</b>	<b>REGULATORY REFORMS</b>	Page 45
-----------	---------------------------	---------

---

<b>08</b>	<b>CANNABINOID DRUGS, MEDICINAL CANNABIS AND OPIOID DRUGS</b>	Page 47
-----------	---	---------

---

# 01

## **REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW**

---

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

---

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

---

3. What are the steps to obtaining authorization to develop, test, and market a product?

---

4. What are the approximate fees for each authorization?

---

5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?

---

6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?

---

7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

8. How is compliance with regulation monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?

---

9. What is the potential range of penalties for noncompliance?

---

10. Is there a national healthcare system? If so, how is it administered and funded?

---

11. How does the government (or public) healthcare system function with private sector healthcare?

---

12. Are prices of drugs and devices regulated and, if so, how?

---

13. How are drugs and devices used by patients paid for? What roles do public and private payers play?

---

14. Who dispenses drugs and devices to patients and how are those dispensers compensated?

---

15. What are the professional and legal responsibilities of those who dispense drugs and devices? What role do they play in providing patient care, information, and safety?

---

# 01 REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

---

## 1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

The main regulatory authorities in Spain are:

- The Spanish Ministry of Health, Consumption and Welfare ('Spanish Ministry of Health'), which is the department of the central Spanish government responsible, among others, for drafting and implementing the rules on pricing and reimbursement of medicinal products that are financed through public funds in Spain.
- The Spanish Medicines Agency of Medicinal Products and Medical Devices (i.e. Agencia Española de Medicamentos y Productos Sanitarios – 'AEMPS'), which is also part of the central Spanish government and is responsible, among others, for granting marketing authorizations for medicinal products (drugs and biologicals) in Spain through the national, mutual-recognition, or decentralized procedures foreseen in the European regulations and with jurisdiction over medical devices and cosmetics as well.

---

## 2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

The Spanish current regulatory framework regarding authorization, pricing and reimbursement of medicinal products, including biologicals, and medical devices includes (i) Royal Decree-Legislative 1/2015, approving the revised text of the Law on Guarantees and Rational Use of Medicinal Products and Medical Devices ('Spanish Law on Medicinal Products'), (ii) Royal Decree 1345/2007 on authorization of industrially manufactured medicinal products, (iii) Royal Decree 271/1990, Royal Decree 83/1993, Order of 17 December 1990 and Order of 6 April 1993 on price and reimbursement, and (iv) Royal Decree 177/2014 establishing the Reference Price System. Likewise, Royal Decree-Law 8/2010 (amended by Royal Decree-Law 9/2011), establishes different mandatory discounts on the ex-factory price of the medicinal product when such medicinal product is dispensed or administered to patient through public funding.

The Spanish current regulatory framework regarding authorization, pricing and reimbursement of medical devices includes (i) Spanish Law on Medicinal Products, (ii) Royal Decree 1591/2009, on medical devices, (iii) Royal Decree 1616/2009, on active implant medical devices, and (iv) Royal Decree 1662/2000, on "in vitro" diagnostic medical devices.

---

## 3. What are the steps to obtain authorization to develop, test, and market a product?

Any person or entity that wishes to manufacture medicinal products or medical devices in Spain, must be previously authorized as manufacturer by the AEMPS, in compliance with the provisions contained in Royal Decree 824/2010 or Royal Decree 1591/2009, as the case may be.

A medicinal product can be placed in the Spanish market if it previously holds a marketing authorization obtained by one of the following procedures: (i) national procedure, mutual-recognition procedure, or decentralized procedure at the AEMPS; or (ii) centralized procedure at the European Medicines Agency.

As regards medical devices, please note that they are divided in four classes (III, IIb, IIa and I), ranked mainly considering the level of invasiveness of the device, the part of the body it is in contact with and the duration of such contact. Except for custom-made devices, all medical devices must bear a CE marking of conformity when they are placed in the market in Spain. The CE marking evidences conformity of the device with the requirements of the applicable laws. For class I devices, such conformity shall be evaluated and declared under the exclusive responsibility of the manufacturer. For class IIa, IIb and III devices, the declaration of conformity requires an evaluation of the device by a notified body (the AEMPS in Spain or any other notified body of another European Union member state). Additionally, for class IIa, IIb and III devices, a communication must be made to the AEMPS the first time that a person places a medical device for distribution or use in the Spanish market.

Furthermore, testing of medicinal products or medical devices must be carried out in accordance with clinical investigation rules, which are mainly contained in Royal Decree 1090/2015 regulating clinical trials.

#### 4. What are the approximate fees for each authorization?

The fees due to the AEMPS to be authorized as manufacturer of medicinal products are EUR 6,035.28. Also, in order to carry out clinical investigation with medicinal products, there are fees due to the AEMPS ranging from EUR 412.12 to EUR 4,327.22.

The fees due to the AEMPS to obtain a marketing authorization for a new medicinal product vary depending on whether such medicinal product is a generic or not:

MARKETING AUTHORIZATION FOR A MEDICINAL PRODUCT (other than a generic)	EUR 21,151.22
MARKETING AUTHORIZATION FOR A GENERIC MEDICINAL PRODUCT	EUR 8,603.75

Besides, the fees due to the AEMPS to be authorized as manufacturer of medical devices are EUR 731.49 plus EUR 103.03. The fees in order to carry out clinical investigation with medical devices are EUR 824.24. No fees are due to the AEMPS in order to place a medical device in the Spanish market; however, if declaration of CE marking of conformity of the device is assessed by the AEMPS as a notified body, then there are fees due to the AEMPS that start in a range of EUR 754.13 to EUR 2,509.81, but may be higher depending on the complexity and scope of the assessment.

Kindly note that these fees are updated yearly according to the Spanish Budget Law. The Spanish Budget Law currently in force is the one for 2018, as the one for 2019 has not been officially approved and published yet.

**5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?**

The marketing authorization of a medicinal product is valid for an initial period of five years. At least nine months before expiration of period, the marketing authorization holder may apply for a marketing authorization renewal, pursuant to article 27 of Royal Decree 1345/2007. Together with the renewal application, the applicant must pay the relevant fees (EUR 2,389.80) and provide a consolidated version of the registration dossier including evaluation data contained in suspected adverse reactions reports and periodic safety update reports, as well as all the variations introduced since the marketing authorization was granted.

Once renewed, the marketing authorization will be valid for an unlimited period, unless the AEMPS requires an additional five-year renewal based on duly justified pharmacovigilance-related reasons.

---

**6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?**

The authorization of both a brand-name medicinal product and a generic medicinal product follow the same legal process. There are only minor differences as regards the fees to be paid to the AEMPS (as explained in [Chapter 1, Question 4](#)) and as regards the application documentation since the authorization procedure of a generic medicinal product does not require the applicant to provide pre-clinical tests and clinical trials results (bioequivalence studies must be provided instead of).

---

**7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?**

There is no specific regulation for combination products in Spain. Please note that biologics are considered as medicinal products and, thus, subject to the same rules.

A combination product comprising both a medicinal product and medical device may be authorized as a medicinal product. E.g. an injectable medicinal product that comes in a pre-filled syringe; such product may be authorized as a medicinal product (although the syringe itself may be authorized as a medical device). It is also possible that a combination product comprising both a medicinal product and medical device is authorized as medical device. E.g. a medical device incorporating as an integral part a substance which, used separately, may be considered as a medicinal product (Judgement of the European Court of Justice in the Case C-527/17 Boston Scientific v Deutsches Patent).

The AEMPS has the final decision on the classification of any such combination product.

---

**8. How is compliance with regulations monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?**

The AEMPS as well as the Health Authorities of the Autonomous Regions (Spain is divided in 17 Autonomous Regions) are in charge of monitoring compliance with the applicable regulations in Spain. As the regulatory regime applicable in Spain is based in EU legislation and guidelines, it is aligned with the European Medicines Agency expectations and requirements.